Comparison of the Efficacy and Safety of Temporary Spinal Cord Stimulation versus Pulsed Radiofrequency for Postherpetic Neuralgia: A Prospective Randomized Controlled Trial
Table 5
Longitudinal results of the pain levels and quality of life for the SCS cohort over time.
Outcome
Time
SCS cohort (n = 20)
-value#
VAS
Baseline
8.0 (8.0-8.3)
Ref
1 week
2.0 (2.0-2.0)
<0.001
1 month
2.0 (2.0-3.0)
<0.001
3 months
2.0 (1.0-3.0)
<0.001
6 months
2.0 (1.0-2.3)
<0.001
-value over time↑
<0.001
SIS
Baseline
7.0 (7.0-8.0)
Ref
1 week
0.0 (0.0-0.3)
<0.001
1 month
0.5 (0.0-2.3)
<0.001
3 months
1.0 (0.0-2.0)
<0.001
6 months
0.5 (0.0-1.3)
<0.001
-value over time↑
<0.001
PHQ-9
Baseline
7.5 (6.0-9.3)
Ref
1 week
3.5 (2.8-6.0)
<0.001
1 month
3.0 (2.0-4.0)
<0.001
3 months
3.0 (2.0-5.0)
<0.001
6 months
2.0 (2.0-3.0)
<0.001
-value over time↑
<0.001
GAD-7
Baseline
6.5 (4.5-9.5)
Ref
1 week
3.0 (0.8-5.0)
0.008
1 month
2.5 (0.8-4.0)
0.004
3 months
2.5(1.0-3.0)
<0.001
6 months
2.0 (1.0-3.0)
<0.001
-value over time↑
<0.001
PF of SF-36
Baseline
55.0 (40.0-70.0)
Ref
1 week
87.5 (75.0-95.0)
<0.001
1 month
85.0 (75.0-95.0)
<0.001
3 months
90.0 (75.0-96.3)
<0.001
6 months
90.0 (75.0-96.3)
<0.001
-value over time↑
<0.001
BP of SF-36
Baseline
31.0 (12.0-43.8)
Ref
1 week
52.0 (52.0-52.0)
<0.001
1 month
52.0 (52.0-62.5)
<0.001
3 months
64.0 (63.5-74.0)
<0.001
6 months
64.0 (63.5-74.0)
<0.001
-value over time↑
<0.001
SCS: spinal cord stimulation; 1st-3rd: 1st-3rd quartiles; VAS: visual analogue scale; SIS: daily sleep interference score; PHQ-9: patient health questionnaire-9; GAD-7: generalized anxiety disorder 7 scale; SF-36: the 36-item short-form health survey; PF: physical function; BP: bodily pain. #-value comparison via post hoc or Wilcoxon signed-rank test. ↑-value represents overall significance over time as per the Friedman test.
